Abstract: The effects of VEGFA isoforms on the vascular permeability and structure are still unclear. In this study, we found that VEGFA121 and VEGFA165, 2 isoforms of VEGFA, exerted the opposing effects of antiangiogenesis and proangiogenesis on regulating vascular endothelia cells proliferation and tube formation. The 2 isoforms affected the protein expression of Ras-related protein 1-GTPase-activating protein 1 (Rap1GAP) and thrombospondin 1, 2 important signal molecules of Rap1GAP/thrombospondin 1 signal pathway in primary human umbilical vein endothelial cells by regulating 2 different phosphorylating sites of VEGFR2, Tyr(1175) and Tyr(1214). We also found that VEGFA121 and VEGFA165 regulating angiogenesis was related to their regulating VEGFR2 and Rap1GAP/thrombospondin 1 signal pathway with the technology of RNA intervening the gene expression of VEGFR2 and Rap1GAP. Meanwhile, 2 inhibitors of VEGFR2, cabozantinib malate and ZM 323881 HCl (ZM), were used to investigate the relationship among VEGFA(121 and 165), VEGFR2, and angiogenesis. It was demonstrated that cabozantinib malate blocked VEGFA121 and VEGFA165 binding to VEGFR2 and inhibited angiogenesis by specifically binding to VEGFR2 rather than changing VEGFR2 phosphorylation or regulating the expression of VEGFR2. However, ZM antagonized the effect of VEGFA on angiogenesis by specifically reversing the phosphorylation induced by VEGFA121 and VEGFA165. The experiments in vivo also demonstrated that obvious abnormality of VEGFA121 and VEGFA165 presented in the serum of ulcerative colitis (UC) rats compared with that of the normal rats. ZM could promote the repairation of the injuries of the vessels and tissues of colonic mucosa of UC rats and caused mild inflammation in colonic mucosa of normal rats. On the contrary, cabozantinib malate caused injury of vessels and inflammation in the colonic mucosa of normal rats and aggravated the injuries of the vessels and inflammation in the colonic mucosa of UC rats. Hence, our data indicated that the activation of different phosphorylation sites of VEGFR2 leaded to VEGFA121 and VEGFA165 exerting opposing effects on angiogenesis, and it might be an underlying pathogenesis of UC and a potential target for UC treatment. (Inflamm Bowel Dis 2017;23:603-616) 
A ngiogenesis, the formation of new capillaries from the preexisting vasculature, plays an important role in the pathogenesis of many diseases, and thus has been targeted for preventing and treating many disorders. 1 Angiogenesis involves proliferation, migration, and tube formation of endothelial cells and reorganization of extracellular matrix 2 and is regulated by many cytokines, such as vascular endothelial growth factor (VEGF), transforming growth factor, and so on. 3 Among these cytokines, VEGFA, an isoform of VEGF, is the most important soluble ligand which promotes the growth and the proliferation of vascular endothelia cells and regulates many aspects of vascular and lymphatic development 4 by binding to VEGFR2, a major receptor and membrane glycoprotein expressed on endothelial cells. 5 The primary RNA transcript of VEGFA encoded by the VEGFA gene on locus 6p21.3 undergoes alternative splicing to produce 7 proangiogenic isoforms and 1 antiangiogenic isoform of VEGFA, such as VEGFA121, VEGFA165, and so on. 6, 7 Current research studies have focused on the VEGFA165 isoform that effectively promotes the growth and the proliferation of human umbilic vein endothelial cells (HUVEC) 8 by programming sequential steps in VEGFR2 tyrosine phosphorylation, ubiquitylation, trafficking, and proteolysis, 9 linking to downstream signal transduction events that trigger pro-angiogenic outcomes such as cells proliferation, migration, tubulogenesis, vascular permeability (VP), and leukocyte recruitment. 4, 10 In addition, other VEGFA isoforms elicited important and distinct biological responses from endothelial cells, 5 but the biological functions and regulatory mechanism of other isoforms of VEGFA (such as VEGFA121 and VEGFA145) in the regulation of angiogenesis are still unclear. Therefore, it is critical to elucidate the potential mechanisms that VEGFA isoforms regulate the proliferation, the migration, and the angiogenesis of HUVEC so that more effective drugs are invented to treat vascular-related diseases.
Furthermore, the previous studies suggested that VEGFA isoforms might elicit different cellular responses by activating different VEGFR2-dependent signal transduction. 11, 12 VEGFA165 and VEGFA121 can stimulate the phosphorylation of the different loci of VEGFR2 and the internalization of the receptor, which subsequently impact on the downstream signal transduction events. Furthermore, the activation of VEGFR2 stimulated by the isoforms of VEGF presents different post-translation modifications of VEGFR2, such as ubiquitylation and proteolysis. 13 However, the underlying mechanisms are not elucidated yet.
Ras-related protein 1-GTPase-activating protein 1 (Rap1-GAP) and thrombospondin-1 (TSP-1), a couple of important signaling proteins in rap-1 signaling pathway that is regulated by VEGFA, are important proteins in regulating proliferation, migration, and angiogenesis of HUVEC. 14, 15 When the expressions of Rap1GAP and TSP-1 are up-regulated in vascular endothelia cells, the proliferation, migration, and angiogenesis are significantly inhibited. 16 However, the effects and the mechanisms of VEGFA121 and VEGFA165 on regulating Rap1GAP/thrombospondin 1 (TSP1) signal pathway are unclear and need for further study.
In the present study, we investigated whether the differences in the effects of VEGFA121 and VEGFA165 on the proliferation, the migration, and the angiogenesis of primary human umbilical vein endothelial cells (pHUVECs) were related to the phosphorylation of VEGFR2 and clarified their potential mechanisms.
MATERIALS AND METHODS
Cell Culture and Animals pHUVECs were obtained from Promo Cell Co. (c-12208, Heidelberg, Germany) and maintained in endothelial growth medium (c-22110) at 378C in a humidified atmosphere of 95% and 5% CO2.
Sprague Dawley Rats (120-140 g) were purchased from Shanghai SLAC Laboratory animal Co. Ltd. (Shanghai, China). All animals used in the study were housed in a pathogen-free environment. The animal experiments were approved by the institutional review board of Shanghai University of TCM. The study began after 1 week of adaptive feeding. Forty-eight rats were randomized into 6 groups of normal control (n ¼ 8), cabozantinib malate (CM) (n ¼ 8), ZM 323881 HCl (ZM) (n ¼ 8), iodoacetamide (IA)-induced ulcerative colitis (UC, n ¼ 8), UC + CM (n ¼ 8), and UC + ZM (n ¼ 8) with SPSS software (Version 20.0; SPSS Inc.). The other 64 Sprague Dawley rats were used to observe the changes of serum VEGFA at different time points within 1 week (0, 1, 3, and 7 d) after IA was used.
Reagents
Evans Blue (dye content was above 75%) and IA (I6125, the purity was above 99%) were purchased from Sigma Chemical Co. 
Cell Viability Assay
The effects of the reagents on the cell viability of pHUVEC were evaluated with the 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-diphenytetra-zoliumromide (MTT; Promega Co., Madison, WI) assay. After pHUVEC was exposed to different concentrations of the reagents for 24 or 48 hours, 20 mL of MTT (5 mg/mL) was added to each well and incubated for 4 hours. Then 150 mL of dimethyl sulfoxide (DMSO) was added in each well. The absorbance was recorded at the wavelength of 490 nm in the microplate reader. The inhibition ratio (I%) was calculated with the following equation: I% 5 ðA490 ½control 2A490 ½treated Þ=A490 ðcontrolÞ · 100 .
Cell Proliferation Assay and Flow Cytometry
To detect the proliferation of the treated pHUVEC, cells were cultured in a 96-well plate. Approximately 1 · 10 4 cells were cultured in each well with serum-free endothelial growth medium for 24 hours. Then the cell culture medium was removed, and the cells were rinsed gently twice with phosphate-buffered saline (PBS). The serum-free medium without VEGF was added in the control group. The culture medium with various treating reagents was added in the corresponding groups. The cells were incubated for 24 hours. At the end, the cells were fixed with 4% paraformaldehyde, tinted with trypan blue and counted. All experiments were performed 3 times.
To detect the apoptotic rate of pHUVEC treated with VEGFA121, the cells were cultured in a 6-well plate. Approximately 3 · 10 5 cells were cultured in each well with serum-free medium for 24 hours. Then the cell culture medium was removed and the cells were rinsed gently twice with PBS. The serum-free medium without VEGF was added in the control group. For the treatment groups, the culture media with various concentrations of VEGFA121 (0.5, 1.0 and 2.0 nM) were added in the treatment groups. The cells were incubated for 24 hours. At the end, the apoptotic rate was detected following the instructions of cell apoptosis detection kit (No: 556547; BD Biosciences, Franklin Lakes, NJ).
Tube Formation Assay
Matrigel assay was performed to observe the endothelial tube formation in vitro as previously described. 17 Fortyeight-well plates (Corning, Toledo, NY) were coated with 200 mL of Matrigel (BD Biosciences) per well and incubated to polymerize at 378C for 30 minutes. pHUVEC were harvested and suspended in fresh serum-free medium without VEGF at the density of 1.5 · 10 5 cells per microliter. Hundred microliters of cell suspension were seeded on the surface of polymerized Matrigel and incubated at 378C for 24 hours. Three or more random pictures of each culture were taken with a Leica fluorescence microscope with digital camera system, and total tube numbers were analyzed. Repeated 3 independent experiments were performed.
Plasmid Construction and Cell Transfection
To clarify the mechanism that VEGF is involved in regulating the proliferation of pHUVEC, the overexpressing and silencing plasmids of VEGFR2 and Rap1GAP were used, respectively. Empty plasmids were used as negative control (NC). The cells were seeded into 24-well plates (Corning). According to the manufacturer's instructions, transfection was performed with Lipofectamine 2000 Transfection Reagent when the cells reached 50% to 80% confluence. Culture medium was changed after 4 to 6 hours, and the cells continued to be incubated at 378C in a CO 2 incubator for 24 hours. Then gene expression was detected with Western blotting. The cells were divided into following groups: control (untransfected), normal control (transfected with empty plasmid), VEGFR2 (+) (VEGFR2 overexpression plasmid), VEGFR2 (2) (VEGFR2 silencing plasmids), Rap1GAP (+) (Rap1GAP over-expression plasmid), and Rap1GAP (2) (Rap1GAP silencing plasmids).
IA-Induced Colitis
Experimental UC was induced in rats with IA. 0.1 mL of 6% IA dissolved in 1% methylcellulose was administrated to the rats once by enema, inserting rubber catheter Nelaton S-8 (Rüschelit, Rüsch, Germany) 7 cm from anus. After 1 day of resting, the rats were treated with CM and ZM.
VEGFR2 Inhibitors in Vivo and Vitro
CM is an effective inhibitor of VEGFR2 with an IC50 of 0.035 nM, and ZM is a selective inhibitor of VEGFR2 with an IC50 of 2.0 nM. But the inhibitory mechanisms of these 2 reagents are unclear. pHUVEC were cultured as above. Then the cell culture medium was removed and the cells were rinsed gently twice with PBS. The serum-free medium without VEGF was added in the control group. The culture media with various treating reagents were added in the corresponding groups. Then the cells were incubated for 24 hours. In the intervention group, 2 different VEGFR2 inhibitors were given to normal rats and IA-induced UC rats once a day by intragastric administration (ig). In the normal control group, normal saline was given to the rats ig once a day.
After 7 days, the rats were anesthetized with 0.18 mL 3% sodium pentobarbital per 100 g. The rats' blood was collected from abdominal aorta, and the rats' colon tissues were taken. The colon tissues were formaldehyde-fixed, paraffin embedded, and HE stained.
VP in Rats
Evans blue was used as described previously to quantitatively evaluate the VP. 18 The rats were anesthetized with intraperitoneal injection of sodium pentobarbital. Evans blue (1 mg/100 g in PBS) was injected intravenously 15 minutes before autopsy. Evans blue was extracted from the colonic tissue (1 cm) using formamide and measured by spectrophotometry at 610 nm. The results were presented as mg per dry weight of colon.
Enzyme-linked Immunosorbent Assay
The serum VEGFA121, VEGFA165, TNF-ɑ, IL-6, IL-4, and IL-10 were measured with rat enzyme-linked immunosorbent assays according to the manufacturer's protocol. Absorbance was measured on a microtiter plate reader.
Microvessel Density
Rat specimens were fixed in buffered formalin, embedded in paraffin and cut into 5-mm-thick serial sections. According to manufacturer's instructions, after heat-mediated antigen retrieval, the tissue was formaldehyde fixed and blocked with the serum. The tissue was incubated with the primary antibody anti CD31 (1:200 vol/vol) overnight at 48C. After three 5-minute washes, the secondary antibody labeled by horseradish peroxidase (HRP) (1:300) was added and the samples were incubated at 378C for 1 hour. The sections were counterstained with Hematoxylin for 1 minute at RT to show the nucleus of cells.
Western Blot Analysis
Cell lysates (Beyotime, Shanghai, China) were added to the plates or colon tissues pulverized and lysed on ice for 30 minutes. Then the lysate was collected and centrifuged for 10 minutes at 10,000 rpm. The supernatant was collected, and the protein content was measured by a BCA protein assay Kit (Beyotime). The protein lysates (20 mL) were separated by electrophoresis on a 20% SDSpolyacrylamide gel and transferred to a PVDF membrane (Millipore, Darmstadt, Germany). The membranes were subsequently blocked with 5% BSA for 2 hours. The membranes were then probed with specific monoclonal antibodies VEGFR2pY1175 (1:1000), VEGFR2pY1214 (1:1000), Rap1GAP (1:10,000), and TSP-1 (1:1000) overnight at 48C. Then the membranes were washed 3 times with TBST. Blots were incubated with secondary antibody for 50 minutes at RT. Antibody-specific proteins were visualized using an enhanced chemiluminescence detection system (Syngene, Cambridge, United Kingdom). Protein densities were quantified by grayscale.
Statistical Analysis
Data obtained from statistical analyses were presented as the mean 6 SD from at least 3 independent experiments. Data sets with 3 or more groups were analyzed with one-way analysis of variance or one-way analysis of variance with repeated measures and the Fisher's least significant difference (LSD) post hoc test for multiple comparisons. Data sets with 2 groups were analyzed using Student's t test. The level of significance was set at a P , 0.05.
RESULTS

Unlike VEGFA165, VEGFA121 Inhibiting the Proliferation and Tube Formation of pHUVEC in Vitro
The effects of VEGFA165 and VEGFA121 on the viability and the proliferation of pHUVEC were measured after 24 hours of conditioned culture. As shown in Figure 1A , B, there was no statistically significant difference in the cell viability and the cell proliferation between 24 and 48 hours in the control group. Compared with the control group, the cell viability and the cell proliferation in the group treated with VEGFA165 were significantly promoted at the concentrations of 0.5, 1.0, and 2.0 nM at 24 hours and at the concentrations of 1.0 and 1.5 nM at 48 hours. But there were no significant differences in the cell viability and the cell proliferation between the concentrations of 1.0 and 1.5 nM at both 24 and 48 hours. Compared with the control group and VEGFA165 treating group, the cell viability and the cell proliferation in the group treated with VEGFA121 were evidently inhibited at the concentrations of 1.0 and 1.5 nM at both 24 and 48 hours. But there were no significant differences between the concentrations of 1.0 and 1.5 nM at both 24 and 48 hours.
To study the mechanism of the inhibitory effect of VEGFA121 on pHUVEC, apoptotic rate of pHUVEC measured with flow cytometry was used to study the apoptosis of the cells treated with VEGFA121 for 24 hours. The apoptosis rates of the control group and the treatment group (treated with VEGFA121 of concentrations of 0.5, 1.0, and 2.0 nM) were 1.23 6 0.23%, 1.33 6 0.27%, 9.78 6 0.82%, and 10.48 6 0.79%, respectively. Compared with the control group, the apoptotic rates of the treatment group treated with concentrations of 1.0 and 2.0 nM were significantly increased (Fig. 1C) .
The results of tube formation experiment demonstrated that the number of the formed tubes of the treatment group treated with VEGFA121 (1.0 and 2.0 nM) were significantly decreased compared with those of the control group and the treatment group treated with VEGFA121 (0.5 nM). On the contrary, the number of the formed tubes of the treatment group treated with VEGFA165 (1.0 and 2.0 nM) were significantly increased compared with those of the control group and the treatment group treated with VEGFA165 (0.5 nM) (Fig. 1D) .
So the results indicated that VEGFA165 could promote the proliferation and the tube formation of pHUVEC as demonstrated in previous studies whereas VEGFA121 had the opposing effects.
CM Inhibiting the Proliferation and the Tube Formation of pHUVEC
The inhibitory effect of CM on the cell viability and the proliferation of pHUVEC were measured after conditioned culturing for 24 hours. As shown in Figure 2A , B, the cell viability and the proliferation of HUVEC of the groups treated with VEGFA121 (1.0 nM), CM (0.1 nM), CM (0.1 nM) + VEGFA121, and CM (0.1 nM) + VEGFA165 significantly decreased compared with those of the control group and the group treated with VEG-FA165. The cell viability and the proliferation of the groups treated with VEGFA121 + CM or VEGFA165 + CM decreased significantly compared with those of the groups treated with VEGFA121 or VEGFA165 alone. But there were no significant differences among the groups treated with CM, VEGFA121 + CM, or VEGFA165 + CM.
The tube formation experiment demonstrated similar results to those of the cell proliferation experiment. VEGFA165 could promote the tube formation. However, compared with the control group and the group treated with VEGFA165 alone, the tube formation of the groups treated with VEGFA121 (1.0 nM), CM (0.1 nM), CM (0.1 nM) + VEGFA165, and CM (0.1 nM) + VEGFA121 decreased significantly. The tube formation of the groups treated with VEGFA121 + CM or VEGFA165 + CM decreased significantly compared with those of the groups treated with VEGFA121 or VEGFA165 alone. But there were no significant differences among the groups treated with CM, VEGFA121 + CM, or VEGFA165 + CM (Fig. 2C) .
The results indicated that CM could inhibit the regulating effects of VEGFA165 and VEGFA121 on pHUVEC proliferation and tube formation.
ZM Reversing the Regulating Effects of VEGFA165 and VEGFA121 on pHUVEC Proliferation and Tube Formation
The inhibitory effect of ZM on pHUVEC viability and proliferation was evaluated after conditioned culturing for 24 hours. As shown in Figure 3A , B, compared with VEGFA165 promoting pHUVEC viability and proliferation and VEGFA121 inhibiting HUVEC viability and proliferation, there were no significant differences in cell viability and proliferation among the groups treated with ZM (10.0 nM), VEGFA121 + ZM (10.0 nM), and VEGFA165 + ZM (10.0 nM). Compared with the groups treated with VEGFA121 or VEGFA165 alone, the regulating effects of VEGFA121 and VEGFA165 on HUVEC viability and proliferation were reversed by ZM in the groups treated with VEGFA121 + ZM and VEGFA165 + ZM.
The tube formation experiment demonstrated the similar results to those of the cell proliferation experiment. VEGFA165 could promote the tube formation whereas VEGFA121 had the opposing effect. However, compared with the control group, the tube formation of the groups treated with ZM (0.1 nM), ZM (0.1 nM) + VEGFA121, and ZM (0.1 nM) + VEGFA165 had no significant change. The regulating effects of VEGFA121 and VEGFA165 on the tube formation were reversed by ZM in the groups treated with VEGFA121 + ZM or VEGFA165 + ZM compared with those of the groups treated with VEGFA121 or VEGFA165 alone (Fig. 3C) .
The results indicated that ZM could reverse the regulating effects of VEGFA165 and VEGFA121 on pHUVEC proliferation and tube formation.
VEGFR2-siRNA Inhibiting the Functions of VEGFA121 and VEGFA165 by Suppressing VEGFR2 Expression
Silencing plasmid of VEGFR2 (VEGFR2-siRNA) was transfected into pHUVEC, and Western blot was used to measure VEGFR2 protein expression after transfection. Compared with the control group and the empty plasmid (Em-p) group, the expression of VEGFR2 protein in pHUVEC was significantly decreased by VEGFR2-siRNA2&3 (Fig. 4A) . So VEGFR2-siRNA2 was selected to as silencing plasmid in the following experiments.
Compared with the control group, there were no significant changes in the expression of VEGFR2 in pHUVEC in the groups treated with VEGFA121 and VEGFA165. But the protein expressions were significantly down-regulated in the groups treated with VEGFA121 + VEGFR2-siRNA, VEGFA165 + VEGFR2-siRNA, and VEGFR2-siRNA and, there were no significant differences among these 3 groups (Fig. 4B) . FIGURE 1. The effect of VEGFA165 and VEGFA121 on cell viability, proliferation, and tubule formation. The cell viability and proliferation in VEGFA165 group was increasing and obvious decreasing in VEGFA121 group; and these analogous trends were also observed at 48 hours (A and B). The apoptotic rate was increased in dose-dependent manner in VEGFA121 group (C); The number of newborn tube in VEGFA121 group was significantly reduced but increased in VEGFA165 group (D). Results were expressed with mean 6 SD of 3 independent experiments performed in triplicate. *P , 0.05, **P , 0.01 significantly different from control without any treatment.
Compared with the control group, pHUVEC proliferation and tube formation significantly decreased in the groups treated with VEGFA121 + VEGFR2-siRNA, VEGFA165 + VEGFR2-siRNA, and VEGFR2-siRNA, and there were no significant differences among these 3 groups.
The regulating effects of VEGFA121 and VEGFA165 on VEGFR2 expression in pHUVEC were not found in this experiment. But the regulating effects of VEGFA121 and VEGFA165 on pHUVEC proliferation and tube formation were reversed by VEGFR2-siRNA (Fig. 4C, D) . So it was concluded that VEGFR2 was the target of VEGFA121 and VEGFA165 regulating pHUVEC proliferation and tube formation. It was not by controlling VEGFR2 expression that VEGFA121 and VEG-FA165 regulated pHUVEC proliferation and tube formation.
Phosphorylation Site of VEGFR2 Might Be the Cause of the Different Function of VEGFA121 and VEGFA165
Phosphorylation, as an important regulation way of VEGFR2 protein activity, widely exists and plays an important role in the regulation of VEGFA function. 13, 19 Based on the above experiments, we found that VEGFR2 was the target receptor of VEGFA121 and VEGFA165 and played an important role in regulating pHUVEC proliferation and tube formation. (A and B) . In addition, the number of tube was increased in VEGFA165 group but significantly reducing in CM, VEGFA121 + CM, VEGFA121, and VEGFA165 + CM groups (C). Results were expressed with mean 6 SD of 3 independent experiments performed in triplicate. **P , 0.01 significantly different from control without any treatment.
As shown in Figure 5A , B, Western blot found that VEG-FA165 significantly up-regulated VEGFR2pY1175 expression level and down-regulated VEGFR2pY1214 expression level in pHUVEC. On the contrary, VEGFA121 significantly downregulated VEGFR2pY1175 expression level and up-regulated VEGFR2pY1214 expression level in pHUVEC. Meanwhile, compared with the groups treated with VEGFA121 or VEGFA165 alone, there were no significant changes in the expressions of VEGFR2pY1214 and VEGFR2pY1175 in pHUVEC in the groups treated with CM + VEGFA121 and CM + VEGVF-A165. But the changes of VEGFR2pY1214 and VEGFR2pY1175 expressions in pHUVEC induced by VEGFA121 and VEGFA165 were reversed by ZM in the groups treated with ZM + VEG-FA121 and ZM + VEGFA165. In addition, TSP1 expression in pHUVEC presented similar changes to VEGFR2p1214 after the phosphorylation of VEGFR2 in pHUVEC induced by VEG-FA121 and VEGFA165.
It was concluded that VEGFA121 and VEGFA165 induced different phosphorylations of VEGFR2 and then regulated the TSP1 expression in pHUVEC. CM could effectively block VEGFA specifically binding to VEGFR2 but could not regulate the phosphorylation of VEGFR2. However, ZM could reverse the FIGURE 3. ZM reversed the functions of VEGFA165 and VEGFA121. Cell viability and proliferation in VEGFA165 group had significantly increased, with significant decreased in VEGFA121 group, but there was no statistically significant difference in ZM, VEGFA121 + ZM, VEGFA165 + ZM and control group (A and B) ; the number of tube in VEGFA165 + ZM group was obviously decreasing, and the function of VEGFA121 was greatly reversed by ZM. And there were no statistically significant differences in control, VEGFA121 + ZM, VEGFA165 + ZM, and ZM group (C). Results were expressed with mean 6 SD of 3 independent experiments performed in triplicate. *P , 0.05, **P , 0.01 significantly different from control without any treatment. FIGURE 4. VEGFR2-siRNA inhibited the function of VEGFA121 and VEGFA165 by inhibiting VEGFR2. The expression of VEGFR2 was significantly downregulated by VEGFR2-siRNA2 and VEGFR2-siRNA3 (A) and the expression level of VEGFR2 protein had no changes in both VEGFA121 and VEGFA165 group, but significantly down-regulated by VEGFR2-siRNA with or without VEGFA121 and VEGFA165 used (B). The proliferation and tube formation were significantly decreased by VEGFR2-siRNA with or without VEGFA121 and VEGFA165 used with no statistically significant difference found among VEGFR2-siRNA, VEGFA121 + VEGFR2-siRNA, and VEGFA165 + VEGFR2-siRNA group (C and D). Results were expressed with mean 6 SD of 3 independent experiments performed in triplicate. *P , 0.05, **P , 0.01 significantly different from control without any treatment. phosphorylation of VEGFR2 induced by VEGFA121 and VEG-FA165 and exerted the inhibitory effect on VEGFR2 further. So ZM could be regarded as a specific VEGFR2 inhibitor by regulating VEGFR2 phosphorylation.
Phospho-VEGFR2 Regulating Rap1GAP/TSP-1 Signaling Way
Silencing plasmid of VEGFR2 (VEGFR2-siRNA) was transfected into pHUVEC, and Western blot was used to detect Rap1GAP protein expression after transfection. Compared with the control group and the Em-p group, the expression of Rap1GAP protein in pHUVEC was significantly decreased by Rap1GAP-siRNA3 (Fig. 6A) . So Rap1GAP-siRNA3 was selected to as silencing plasmid in the following experiments. In addition, the overexpressing plasmids of VEGFR2 (VEGFR2-ov) and Rap1GAP (Rap1GAP-ov) were transfected into pHUVEC. The expressions of Rap1GAP and VEGFR2 protein were significantly up-regulated by Rap1GAP-ov and VEGFR2-ov compared with the control group and the group transfected by Em-p.
As shown in Figure 5B -E the control group was shared in this experiment and the related operations were performed simultaneously. Compared with the control group, the expressions of VEGFR2 protein were significantly down-regulated in the groups treated with VEGFR2-siRNA, VEGFR2-siRNA + VEGFA121, FIGURE 5 . Different phosphorylation sites of VEGFR2 might be one reason that VEGFA121 and VEGFA165 had different functions. The expression level of VEGFR2pY1175 was significantly increased in VEGFA165 group and clearly reduced in VEGFA121 group; and the expression level of VEGFR2pY1214 showed the opposite trend. Besides, versus groups only treated by VEGFA121 or VEGFA165, the expression level of VEGFR2pY1175 and VEGFR2pY1214 was not changed by CM but significantly reversed by ZM. In addition, there was no statistically significant difference in groups treated by ZM and group only treated by CM (A and B) ; Besides, the expression of TSP1 protein had the same trend as the expression of VEGFR2p1214 protein (A and B). Results were expressed with mean 6 SD of 3 independent experiments performed in triplicate. *P , 0.05, **P , 0.01 significantly different from control without any treatment.
and VEGFR2-siRNA + VEGFA165. Meanwhile, the expressions of Rap1GAP and TSP1 in pHUVEC were significantly up-regulated in the groups treated with VEGFA121, VEGFR2-siRNA, VEGFR2-siRNA + VEGFA121, VEGFR2-siRNA + VEG-FA165, Rap1GAP-over, Rap1GAP-over + VEGFA121, and Rap1GAP-over + VEGFA165. But there were no significant changes in the expression of VEGFR2 among the groups treated with VEGFR2-siRNA, VEGFR2-siRNA + VEGFA121, and VEGFR2-siRNA + VEGFA165. Meanwhile, there were no significant changes in the expression of Rap1GAP among the groups treated with Rap1GAP-over, Rap1GAP-over + VEGFA121, and Rap1GAP-over + VEGFA165.
On the contrary, the expression of VEGFR2 was significantly up-regulated in pHUVEC in the groups treated with VEGFR2-over, VEGFR2-over + VEGFA121, and VEGFR2-over + VEGFA165. Meanwhile, the expressions of Rap1GAP and TSP1 were significantly down-regulated in the groups treated with VEGFA165, VEGFR2-over, VEGFR2-over + VEGFA121, FIGURE 6 . Rap1GAP/TSP-1 signaling was activated by phospho-VEGFR2. Silencing plasmid of Rap1GAP (Rap1GAP-siRNA) and VEGFR2-siRNA and overexpressing plasmid of Rap1GAP (Rap1GAP-ov) was transfected. The expression of Rap1GAP protein was significantly down-regulated by Rap1GAP-siRNA3 with the expression of Rap1GAP and VEGFR2 protein up-regulated by Rap1GAP-ov and VEGFR2-ov (A); Besides, the expression of VEGFR2 protein was significantly up-regulated by VEGFR2-ov and distinctly down-regulated by VEGFR2-siRNA with or without VEGFA121 and VEGFA165 used; Meanwhile, the expression level of TSP-1 proteins had the same trend as the change of Rap1GAP protein and opposite trend as the expression of VEGFR2 (B-E); results were expressed with mean 6 SD of 3 independent experiments performed in triplicate. *P , 0.05, **P , 0.01 significantly different from control without any treatment.
VEGFR2-over + VEGFA165, Rap1GAP-siRNA, Rap1GAP-siR-NA + VEGFA121, and Rap1GAP-siRNA + VEGFA165. There were no significant differences in the expression of VEGFR2 among the groups treated with VEGFR2-over, VEGFR2-over + VEGFA121, and VEGFR2-over + VEGFA165. Meanwhile, there were no significant differences in the expression of Rap1GAP among the groups treated with Rap1GAP-siRNA, Rap1GAP-siR-NA + VEGFA121, and Rap1GAP-siRNA + VEGFA165.
It was speculated that the phosphorylation of VEGFR2 could regulate pHUVEC proliferation and tube formation by regulating Rap1GAP/TSP-1 signaling pathway.
Reversing the Phosphorylation of VEGFR2 Maintaining the Integrity of the Blood Vessels
To further explore the possible role of VEGFR2 in the regulation of angiogenesis in vivo, the normal rats and IA-induced UC rats (as an animal model of inflammation) were used to explore the expression of VEGFA121 and VEGFA165 and their functions in angiogenesis regulation in the physiological and pathological modes. This experiment demonstrated that proinflammatory cytokines (IL-2 and TNF-alpha) increased and antiinflammatory cytokines (IL-4 and IL-10) decreased in relation to the aggravation of the blood vessels injury in the UC rats' colon tissues (Fig. 7F) . The serum contents of VEGFA121 and VEG-FA165 increased significantly in UC rats compared with the normal rats. The ratio of VEGFA165/VEGFA121 was higher in UC rats than in the normal rats. The normal rats and the UC rats were treated with CM and ZM, respectively (Fig. 7A, B) . We found that CM caused the damages of the microvessels and colonic mucosa and increased permeability of the microvessels in both normal rats and the UC rats ( Fig. 7B-E) . Different from CM, ZM was used to treat the normal rats for 7 days and caused little damage to colonic mucosa, microvessels, and permeability of microvessels except for a little effect on IL-4, IL-10, and TNFalpha. In addition, ZM could obviously promote the repairation of colonic mucosa, microvessels, and permeability of microvessels, FIGURE 7 . Reversing the phosphorylation of VEGFR2 maintained the integrity of the blood vessels. The normal Sprague Dawley rats and IAinduced UC rats were used to explore the function of VEGFR2 inhibitors (CM and ZM) in the regulating angiogenesis. The content of VEGFA121 and VEGFA165 were measured by enzyme-linked immunosorbent assay kit (A and B); After the normal rats and IA-induced UC Rats were treated by CM (80 mg/100 g, ig) or CM (20.0 nM/100 g, ig). The damages of VP, mucosal microvascular and colon mucosa were evidently aggravated, with the rates of VEGFA121/VEGFA165 increasing (B-E), the content of TNF-a, IL-6, IL-4 and IL-10 had changed (F). Results were expressed with mean 6 SD of 3 independent experiments performed in triplicate. *P , 0.05, **P , 0.01 significantly different from control without any treatment.
reduce the proinflammatory cytokines (IL-2 and TNF-alpha), and increase the anti-inflammatory cytokines (IL-4 and IL-10) in the serum (Fig. 7F) .
It was speculated that reversing the abnormality of VEGFR2 phosphorylation induced by the abnormal ratio of VEGFA165/VEGFA121 could effectively promote the repairation of the damage of colonic mucosa and microvessels and maintain the integrity of the vessel structure.
DISCUSSION
As characteristically pathological changes in many diseases, angiogenesis and the damage of blood vessels are important factors affecting the structure and the function of blood vessels in the body. So ascertaining the mechanisms of angiogenesis and the damage of blood vessels plays an important role in treating various diseases including cancers, UC, 20 and cardiovascular diseases. VEGFA is a cytokine secreted by various cells. It plays import roles in maintaining vascular homeostasis by regulating angiogenesis or affecting VP. 21 VEGFA has many isoforms, such as VEGFA165, VEGFA121, VEGFA145, and so on. 22 Among them, VEGFA165, as an important cytokine regulating angiogenesis, has been studied most. It has been demonstrated that VEGFA165 can promote the proliferation and the growth of vascular endothelia cells and increase the density of new blood vessels in the tissue. 23 Its mechanism maybe related to regulating VEGF signaling pathway and has not been clear yet. In addition, the functions of other VEGFA isoforms, such as VEGF121 and VEGF145, in angiogenesis regulation have not been clear yet.
In recent years, the studies demonstrated that the contents of VEGFA165 and VEGFA121 were obviously different in the tissues of colorectal cancers compared with the normal colon tissues. The 2 isoforms have the opposite effects on the growth of tumors. The ratios of VEGFA165/VEGFA121 in the patients with cancers or inflammation increased more obviously than that in the health. In the patients with cancers, the increasing of the ratio promoted the proliferation and the metastasis of the tumor cells by affecting the vessel density and the structure and the function of the vessels. 7, 24, 25 IA-induced UC rat was used as a model of inflammation in this study. It was found that both the contents of VEGFA165 and VEGFA121 increased obviously in the rats serum. The more the ratio of VEGFA165/VEGFA121 in the rats serum increased, the more obvious the vessels in the rats colon mucosa tissues were damaged.
In addition, the effects of VEGFA165 and VEGFA121 on regulating the proliferation and growth of pHUVEC were studied further in vitro. Like the results of previous studies, we found that VEGFA165 obviously promoted the proliferation of pHUVEC and angiogenesis in vitro. But there has not been a unanimous and persuasive conclusion on the effect of VEGFA121 on angiogenesis regulation.
In previous studies, most of the researchers deemed that VEGFA promoted angiogenesis. 26, 27 However, the recent studies found that the increasing level of VEGFA might inhibit angiogenesis and aggravate the vessel damage. 7, 28, 29 In our study, we found that VEGFA had a certain inhibitory effect on pHUVEC proliferation and angiogenesis in vitro. This explained in some extent why the content of VEGFA121 increased in IA-induced UC rats and the damage of the vessels in colon mucosa aggravated. But its mechanism has not been clear.
Related studies focused on programs sequential steps in tyrosine phosphorylation, ubiquitylation, trafficking, and proteolysis of VEGFR2 activated by VEGFA121 and VEGFA165, 13, 30, 31 which linked to downstream signal transduction events that trigger proangiogenic outcomes such as cell proliferation, migration, tubulogenesis, VP, and leukocyte recruitment. 4, 11 Besides, it is confirmed that other VEGFA isoforms elicit important and distinct biological responses to endothelial cells by regulating different VEGFR2-dependent signal transductions. 5, 12, 13 In our experiment, we used CM, ZM, and VEGFR2-siRNA to intervene VEGFR2 and found that both of the receptors of VEGFA165 and VEGFA121 were VEGFR2. But why VEGFA165 and VEGFA121 regulated the same receptor and had different biological responses has not been clear yet.
In this study, we found that the different roles of VEGFA121 and VEGFA165 in regulating cell proliferation and tube formation could be related to the different phosphorylation sites of VEGFR2 rather than the different expression levels and specific binding capacities of VEGFR2. VEGFR2pY1175 was down-regulated and VEGFR2pY1214 was up-regulated in pHU-VEC by VEGFA121. On the contrary, VEGFR2pY1175 was upregulated and VEGFR2pY1214 was down-regulated in pHUVEC by VEGFA165. ZM could effectively reverse the phosphorylation of VEGFR2 while CM had no obvious effect on the phosphorylation of VEGFR2.
Meanwhile, it was found in our study that both the inhibitory effect of VEGFA121 and the promoting effect of VEGFA165 on pHUVEC proliferation and tube formation could be reversed by ZM, the specific inhibitor of VEGFR2. CM is known as an inhibitor of VEGFR2 to block the function of VEGFA. 32 Results in our experiment suggested that the potential roles of VEGFA121 and VEGFA165 on regulating cell proliferation and tube formation in vitro and angiogenesis and VP in vivo could be blocked by CM. So CM and ZM could be used as 2 intervening agents in the experiments and played different roles in regulating the function of VEGFR2.
In this experiment, the normal rats and the IA-induced UC rats were used to reflect the 2 modes of the ratio of VEGFA165/ VEGFA121. Compared with the rats not treated with CM, the damages of colonic mucosa and microvessels in colonic mucosa in both the normal rats and the UC rats were more obvious after being treated with CM. However, the damage of microvessels in colonic mucosa in the UC rats was alleviated after being treated with ZM. Except for slight abnormality in proinflammatory cytokines, there was no obvious damage in the microvessels in colonic mucosa in the normal rats. Therefore, we concluded that VEGFA121 could inhibit the pHUVEC proliferation and tube formation via upregulating VEGFR2p1214 and down-regulating VEGFR2p1175 and aggravate the vessel damage. On the contrary, VEGFA165 could promote the angiogenesis by regulating phosphorylation of VEGFR2 in the opposite way. ZM inhibited the function of VEGFR2 by blocking its phosphorylation.
But the mechanism of angiogenesis regulation after VEGFR2 activation has not been clarified. Previous studies demonstrated that several signal transduction pathways were involved in the signal transduction after VEGFR2 activation, such as VEGF signaling, Akt signaling, and so on. 33, 34 Among them, the overexpression of Rap1GAP1, a GTPase-activating protein inhibiting Rap1 activity, could effectively regulate angiogenesis by inhibiting EC proliferation, tube formation, cell migration, and integrin-dependent adhesion. 35, 36 Rap1a and Rap1b are essential for the conformational activation of beta(1)-integrins in endothelial cells. Furthermore, silencing of Rap1a and Rap1b prevented phosphorylation of tyrosine 397 in vascular endothelial growth factor-induced Akt1-activation. 14 VEGF could reverse the inhibitory effect on the proliferation and tube formation of pHU-VEC induced by the overexpression of Rap1GAP. 16 Besides, TSP-1, a major protein for driving endothelial cell senescence, could also inhibit angiogenesis directly by interacting with VEGF and indirectly by engaging several endothelial cell TSP-1 receptors. [37] [38] [39] So it could be speculated that both Rap1GAP and TSP-1 were critical signal transduction molecules in the process that VEGF, targeting VEGFR2, regulated the proliferation of pHUVEC and angiogenesis in vivo. However, the potential relationship among VEGFR2, TSP-1, and Rap1GAP is unclear.
Therefore, through silencing and overexpressing plasmids of VEGFR2 and Rap1GAP, our study found that the mechanism of VEGFR2 regulating EC proliferation and angiogenesis might depend on VEGFR2-Rap1GAP/TSP-1 signaling pathway.
In summary, VEGFA121 and VEGFA165 might play different roles in regulating the EC proliferation in vitro and the angiogenesis in vivo. The potential mechanisms might be related to the different phosphorylation points of VEGFR2 induced by VEGFA121 and VEGFA165, which further affected the EC proliferation and the angiogenesis by VEGFR2-Rap1GAP/TSP-1 signaling pathway. On the contrary, reversing the phosphorylation of VEGFR2 could effectively reverse the microvessels lesion in both physiological or pathological states.
However, our study could not clarify the causes of the abnormal expression of VEGFA121 and VEGFA165 and the mechanism of TSP-1 inhibiting angiogenesis. Although Fang et al reported that the increasing TSP1 in colon mucosa in UC could induce transforming growth factor-b+ differentiation of lamina propria mononulcear cell and regulate the idiopathic immune function, 39 there are still many questions to be answered. So to study these questions further is necessary for clarifying the mechanisms of angiogenesis and vascular lesions, which are essential in the prevention and the treatment of vascular diseases.
